Another Milestone Met: Licensing Potential For ChromaDex's (CDXC) pTeroPure

MOVED TO:  http://vfcsstockhouse.com/blog/article/-another-milestone-met-licensing-potential-for-chromadex-s-cdxc-pteropure
.

Stock Watch: CYTR One To Watch For Those That Believe Volume Precedes Price

MOVED TO:  http://vfcsstockhouse.com/blog/article/-stock-watch-cytr-one-to-watch-for-those-that-believe-volume-precedes-price

CDXC: By Combining The Power Of Nature With Solid Science, ChromaDex Corp (CDXC) Has Positioned Itself For Huge Growth

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cdxc-by-combining-the-power-of-nature-with-solid-science-chromadex-corp-cdxc-has-positioned-itself-for-huge-growth
.

Generex (GNBT) Defends Itself Against Recent Statements

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-gnbt-defends-itself-against-recent-statements

Cel-Sci Partner Initiates Trial In Israel

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cel-sci-partner-initiates-trial-in-israel

SIGA Shares Could Fly (Again) On BARDA Contract

MOVED TO:  http://vfcsstockhouse.com/blog/article/-siga-shares-could-fly-again-on-barda-contract

EPCT: Adding Another Arm To Ceplene Trial?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-epct-adding-another-arm-to-ceplene-trial-

Stocks To Watch This Week: DNDN, MNKD, CLDX, CDXC, CELH, ONTY, IMUC, and more...

MOVED TO:  http://vfcsstockhouse.com/blog/article/-stocks-to-watch-this-week-dndn-mnkd-cldx-cdxc-celh-onty-imuc-and-more-

The Good, The Bad & The Ugly: Is Labopharm (DDSS) Done?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-the-good-the-bad-the-ugly-is-labopharm-ddss-done-

Generex Drops

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-drops

Cel-Sci's (CVM) Partner Orient Europharma To Commence Phase III In Taiwan

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cel-sci-s-cvm-partner-orient-europharma-to-commence-phase-iii-in-taiwan

Other Market Opportunities For Cel-Sci? Not Sure It's Relevant

MOVED TO:   http://vfcsstockhouse.com/blog/article/-other-market-opportunities-for-cel-sci-not-sure-it-s-relevant

IMUC: Take Notice Of This Company Growing Potential

MOVED TO:  http://vfcsstockhouse.com/blog/article/-imuc-take-notice-of-this-company-growing-potential

SIGA: Are High-Profile Conflicts-of-Interest Playing A Role In Congressional Questioning?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-siga-are-high-profile-conflicts-of-interest-playing-a-role-in-congressional-questioning-

EPCT: Theme Of Shareholder Meeting Is Reverse Split

MOVED TO:  http://vfcsstockhouse.com/blog/article/-epct-theme-of-shareholder-meeting-is-reverse-split

Generex Provides Long-Awaited Oral-Lyn Update

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-provides-long-awaited-oral-lyn-update

Stocks to Watch This Week: SIGA, CPST, CELH, IMUC, TTNP, SIRI, CDXC, CLDX, ONTY

MOVED TO:  http://vfcsstockhouse.com/blog/article/-stocks-to-watch-this-week-siga-cpst-celh-imuc-ttnp-siri-cdxc-cldx-onty

Stock Watch: ACTC Trials Underway, History In The Making?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-stock-watch-actc-trials-underway-history-in-the-making-

Generex: Gearing Up For A Move Into The Future

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-gearing-up-for-a-move-into-the-future

CVM: Are You Hungary For News?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cvm-are-you-hungary-for-news-

CELH: Could Be Time To Throw This One Back On The Radar Screen

MOVED TO:  http://vfcsstockhouse.com/blog/article/-celh-could-be-time-to-throw-this-one-back-on-the-radar-screen

Watch-List These Cancer Companies: IMUC, AGEN, DNDN, CYTR, KERX

MOVED TO:  http://vfcsstockhouse.com/blog/article/-watch-list-these-cancer-companies-imuc-agen-dndn-cytr-kerx

CYTR: Positive Phase II Preliminaries Demonstrate Growing Potential Of Company

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cytr-positive-phase-ii-preliminaries-demonstrate-growing-potential-of-company

Immunocellular Therapeutics: Ushering In The Next Generation Of Cancer Immunotherapies

MOVED TO:  http://vfcsstockhouse.com/blog/article/-immunocellular-therapeutics-ushering-in-the-next-generation-of-cancer-immunotherapies

Stocks To Watch This Week: CYTR, GILD, RPC, AVNR, MCLN, GNBT, CPST, FCEL & More...

MOVED TO:  http://vfcsstockhouse.com/blog/article/-stocks-to-watch-this-week-cytr-gild-rpc-avnr-mcln-gnbt-cpst-fcel-more-

CPST: Is The Fool Going Positive On Capstone?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cpst-is-the-fool-going-positive-on-capstone-

GNBT: Reverse Split Is A Go, But Is GNBT A Buy Again?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-gnbt-reverse-split-is-a-go-but-is-gnbt-a-buy-again-

Looking For The Next Dendreon? Try CytRx

MOVED TO:  http://vfcsstockhouse.com/blog/article/-looking-for-the-next-dendreon-try-cytrx

Positive Analyst Coverage And New Orders Keep Capstone In The News

MOVED TO:  http://vfcsstockhouse.com/blog/article/-positive-analyst-coverage-and-new-orders-keep-capstone-in-the-news

Cytosorbents' Letter to Shareholders Emphasizes Patience and Potential

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cytosorbents-letter-to-shareholders-emphasizes-patience-and-potential

Will Epicept's Nasdaq Lifeline Be Enough To Keep It Listed?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-will-epicept-s-nasdaq-lifeline-be-enough-to-keep-it-listed-

Generex: Dips Below Twenty Cents As GMD Deal Is Announced As Cancelled

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-dips-below-twenty-cents-as-gmd-deal-is-announced-as-cancelled

Stocks to Watch This Week: CTSO, GNBT, APRI, MCET

MOVED TO:  http://vfcsstockhouse.com/blog/article/-stocks-to-watch-this-week-ctso-gnbt-apri-mcet

Oncothyreon: Is The Continued Run Setting A Trend Or The Result Of Increased Exposure?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-oncothyreon-is-the-continued-run-setting-a-trend-or-the-result-of-increased-exposure-

Want Proof That The FDA Doesn't Like The Little Guys? Take A Look At BioDelivery Sciences

MOVED TO:  http://vfcsstockhouse.com/blog/article/-want-proof-that-the-fda-doesn-t-like-the-little-guys-take-a-look-at-biodelivery-sciences

CTSO: Interesting Late Day Action Friday

MOVED TO:  http://vfcsstockhouse.com/blog/article/-ctso-interesting-late-day-action-friday

Titan: Still On The Watch List

MOVED TO:  http://vfcsstockhouse.com/blog/article/-titan-still-on-the-watch-list

Generex's New Dividend Announcement, Last Ditch Attempt To Buy A Few More Votes?

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-s-new-dividend-announcement-last-ditch-attempt-to-buy-a-few-more-votes-

CytRx (CYTR) Bubbling With Potential: A Strong Pipeline and Non-Dilutive Financing Bodes Well For Future Value

MOVED TO:  http://vfcsstockhouse.com/blog/article/-cytrx-cytr-bubbling-with-potential-a-strong-pipeline-and-non-dilutive-financing-bodes-well-for-future-value

Generex Announces Licensing Agreement

MOVED TO:  http://vfcsstockhouse.com/blog/article/-generex-announces-licensing-agreement

Epicept Announces Financing

MOVED TO:  http://vfcsstockhouse.com/blog/article/-epicept-announces-financing

Multicell Breaks Through Two Cents

MOVED TO:  http://vfcsstockhouse.com/blog/article/-multicell-breaks-through-two-cents

Avanir - Still Holds Long Term Potential, But Keep An Eye On Short Term Risks

MOVED TO:  http://vfcsstockhouse.com/blog/article/-avanir-still-holds-long-term-potential-but-keep-an-eye-on-short-term-risks